AAAAAA
Results: 26-50/62
Authors:
SCHENTAG JJ
NIX DE
FORREST A
ADELMAN MH
Citation: Jj. Schentag et al., AUIC - THE UNIVERSAL PARAMETER WITHIN THE CONSTRAINT OF A REASONABLE DOSING INTERVAL, The Annals of pharmacotherapy, 30(9), 1996, pp. 1029-1031
Authors:
SCHENTAG JJ
CARR JR
ADELMAN MH
BIRMINGHAM MC
PALADINO JA
ZIMMER G
CUMBO TJ
Citation: Jj. Schentag et al., FORMULARY MANAGEMENT VS DISEASE MANAGEMENT, Infectious diseases in clinical practice, 5, 1996, pp. 42-47
Authors:
LUZIER AB
ADELMAN M
SCHENTAG JJ
HAWARI F
KORMOS A
IZZO JL
Citation: Ab. Luzier et al., DATABASE ANALYSIS OF RISK OF READMISSION FOR CONGESTIVE-HEART-FAILUREIN PATIENTS TREATED WITH ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS ANDDIGOXIN, Circulation, 94(8), 1996, pp. 1129-1129
Authors:
SCHENTAG JJ
Citation: Jj. Schentag, UNDERSTANDING AND MANAGING MICROBIAL RESISTANCE IN INSTITUTIONAL SETTINGS, American journal of health-system pharmacy, 52(6), 1995, pp. 9-14
Authors:
SCHENTAG JJ
Citation: Jj. Schentag, ANTIBIOTIC-TREATMENT OF ACUTE OTITIS-MEDIA IN CHILDREN - DOSING CONSIDERATIONS, The Pediatric infectious disease journal, 14(4), 1995, pp. 30-33
Authors:
NIX DE
SCHENTAG JJ
Citation: De. Nix et Jj. Schentag, ROLE OF PHARMACOKINETICS AND PHARMACODYNAMICS IN THE DESIGN OF DOSAGESCHEDULES FOR 12-H CEFOTAXIME ALONE AND IN COMBINATION WITH OTHER ANTIBIOTICS, Diagnostic microbiology and infectious disease, 22(1-2), 1995, pp. 71-76
Authors:
HYATT JM
MCKINNON PS
ZIMMER GS
SCHENTAG JJ
Citation: Jm. Hyatt et al., THE IMPORTANCE OF PHARMACOKINETIC-PHARMACODYNAMIC SURROGATE MARKERS TO OUTCOME - FOCUS ON ANTIBACTERIAL AGENTS, Clinical pharmacokinetics, 28(2), 1995, pp. 143-160
Authors:
BLUM RA
SCHENTAG JJ
GARDNER MJ
WILNER KD
Citation: Ra. Blum et al., THE EFFECT OF TENIDAP SODIUM ON THE DISPOSITION AND PLASMA-PROTEIN BINDING OF PHENYTOIN IN HEALTHY MALE-VOLUNTEERS, British journal of clinical pharmacology, 39, 1995, pp. 35-38
Authors:
TENG RL
HARRIS SC
NIX DE
SCHENTAG JJ
FOULDS G
LISTON TE
Citation: Rl. Teng et al., PHARMACOKINETICS AND SAFETY OF TROVAFLOXACIN (CP-99,219), A NEW QUINOLONE ANTIBIOTIC, FOLLOWING ADMINISTRATION OF SINGLE ORAL DOSES TO HEALTHY MALE-VOLUNTEERS, Journal of antimicrobial chemotherapy, 36(2), 1995, pp. 385-394
Authors:
KOSOGLOU T
KAZIERAD DJ
SCHENTAG JJ
PATRICK JE
HEIMARK L
RADWANSKI E
CHRISTOPHER D
FLANNERY BE
AFFRIME MB
Citation: T. Kosoglou et al., EFFECT OF FOOD ON THE ORAL BIOAVAILABILITY OF ISOSORBIDE-5-MONONITRATE ADMINISTERED AS AN EXTENDED-RELEASE TABLET, Journal of clinical pharmacology, 35(2), 1995, pp. 151-158
Authors:
KAZIERAD DJ
WOJCIK GJ
NIX DE
GOLDFARB AL
SCHENTAG JJ
Citation: Dj. Kazierad et al., THE EFFECT OF VERAPAMIL ON THE NEPHROTOXIC POTENTIAL OF GENTAMICIN ASMEASURED BY URINARY ENZYME EXCRETION IN HEALTHY-VOLUNTEERS, Journal of clinical pharmacology, 35(2), 1995, pp. 196-201
Authors:
HYATT JM
NIX DE
STRATTON CW
SCHENTAG JJ
Citation: Jm. Hyatt et al., IN-VITRO PHARMACODYNAMICS OF PIPERACILLIN, PIPERACILLIN-TAZOBACTAM, AND CIPROFLOXACIN ALONE AND IN COMBINATION AGAINST STAPHYLOCOCCUS-AUREUS, KLEBSIELLA-PNEUMONIAE, ENTEROBACTER-CLOACAE, AND PSEUDOMONAS-AERUGINOSA, Antimicrobial agents and chemotherapy, 39(8), 1995, pp. 1711-1716
Authors:
BLUM RA
KAMIMURA H
HIGUCHI S
OCHIAI H
SCHENTAG JJ
Citation: Ra. Blum et al., PHARMACOKINETICS OF YM617 IN SUBJECTS WITH HEPATIC INSUFFICIENCY, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 149-149
Authors:
SCHENTAG JJ
DANDREA DT
BLUM RA
Citation: Jj. Schentag et al., NONINVASIVE MONITORING OF GI TRACT TRANSIT-TIME AND MOTILITY USING THE SITE-SPECIFIC DRUG-DELIVERY CAPSULE (SSDDC), Clinical pharmacology and therapeutics, 57(2), 1995, pp. 171-171
Authors:
BLUM RA
KAMIMURA H
HIGUCHI S
OCHIAI H
SCHENTAG JJ
Citation: Ra. Blum et al., PHARMACOKINETICS OF YM617 IN SUBJECTS WITH RENAL-INSUFFICIENCY, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 218-218
Authors:
GOSS TF
FORREST A
NIX DE
BALLOW CH
BIRMINGHAM MC
CUMBO TJ
SCHENTAG JJ
Citation: Tf. Goss et al., MATHEMATICAL EXAMINATION OF DUAL INDIVIDUALIZATION PRINCIPLES .2. THERATE OF BACTERIAL ERADICATION AT THE SAME AREA UNDER THE INHIBITORY CURVE IS MORE RAPID FOR CIPROFLOXACIN THAN FOR CEFMENOXIME, The Annals of pharmacotherapy, 28(7-8), 1994, pp. 863-868
Authors:
FASS RJ
NIGHTINGALE C
BERGAN T
MEYER RD
MODAI J
RAMIREZ IA
SCHENTAG JJ
Citation: Rj. Fass et al., SEQUENTIAL THERAPY, PARENTERAL TO ORAL - PANEL DISCUSSION, Infectious diseases in clinical practice, 3, 1994, pp. 190000166-190000167
Authors:
BEAM TR
DAVEY P
MACCONNACHIE A
NIGHTINGALE C
SCHENTAG JJ
Citation: Tr. Beam et al., DRUG-INTERACTIONS AND PATIENT EDUCATION - PANEL DISCUSSION, Infectious diseases in clinical practice, 3, 1994, pp. 190000190-190000194
Authors:
LI RC
NIX DE
SCHENTAG JJ
Citation: Rc. Li et al., INTERACTION BETWEEN CIPROFLOXACIN AND METAL-CATIONS - ITS INFLUENCE ON PHYSICOCHEMICAL CHARACTERISTICS AND ANTIBACTERIAL ACTIVITY, Pharmaceutical research, 11(6), 1994, pp. 917-920
Authors:
PALADINO JA
RAINSTEIN MA
SERRIANNE DJ
PRZYLUCKI JE
WELAGE LS
COLLURA ML
SCHENTAG JJ
Citation: Ja. Paladino et al., AMPICILLIN-SULBACTAM VERSUS CEFOXITIN FOR PROPHYLAXIS IN HIGH-RISK PATIENTS UNDERGOING ABDOMINAL-SURGERY, Pharmacotherapy, 14(6), 1994, pp. 734-739
Authors:
PECK CC
BARR WH
BENET LZ
COLLINS J
DESJARDINS RE
FURST DE
HARTER JG
LEVY G
LUDDEN T
RODMAN JH
SANATHANAN L
SCHENTAG JJ
SHAH VP
SHEINER LB
SKELLY JP
STANSKI DR
TEMPLE RJ
VISWANATHAN CT
WEISSINGER J
YACOBI A
Citation: Cc. Peck et al., OPPORTUNITIES FOR INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN RATIONAL DRUG DEVELOPMENT, Journal of clinical pharmacology, 34(2), 1994, pp. 111-119
Authors:
AMSDEN GW
GOSS TF
HARRISON NJ
DANDREA DT
SCHENTAG JJ
Citation: Gw. Amsden et al., PHARMACODYNAMICS OF BOLUS FAMOTIDINE VERSUS INFUSED CIMETIDINE, RANITIDINE, AND FAMOTIDINE, Journal of clinical pharmacology, 34(12), 1994, pp. 1191-1198
Authors:
FINK MP
SNYDMAN DR
NIEDERMAN MS
LEEPER KV
JOHNSON RH
HEARD SO
WUNDERINK RG
CALDWELL JW
SCHENTAG JJ
SIAMI GA
ZAMECK RL
HAVERSTOCK DC
REINHART HH
ECHOLS RM
HELSMOORTEL C
SOJASTRZEPA D
SCHWAITZBERG S
BAREFOOT L
FEIN AM
FEINSILVER SH
ILOWITE JS
CLARE N
SCHULMAN D
JONES CB
GRIFFIN RI
WROBEL CW
BALLOW CH
AMSDEN G
MITCHELL P
BESS T
WILKINS W
BROWN RB
MCGEE W
SAFFORD MJ
LEVINE DP
LERNER SA
KRUSE JA
BANDER JJ
MCNEIL P
MUNKARAH M
SUMMER WR
DEBOISBLANC B
LEVISON ME
KORZENIOWSKI O
SIGLER A
BALDASSARRE J
WALSH P
SAMEL C
SESSLER CN
POLK RE
ISRAEL DS
TONER J
TRAUB SL
KARRAS G
TOURVILLE D
KHAN F
KARNIK A
SCHWORER PB
MOSER RJ
LAGEMAN DJ
GREENE WH
DONELAN SV
FREI L
VITALE S
PONS VG
OCTAVIO J
RUBIN LJ
BRAUN SR
HINSON JM
PRENGER S
PRYKA RD
WAINZ R
HORTON F
HAIG GM
Citation: Mp. Fink et al., TREATMENT OF SEVERE PNEUMONIA IN HOSPITALIZED-PATIENTS - RESULTS OF AMULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING INTRAVENOUS CIPROFLOXACIN WITH IMIPENEM-CILASTATIN, Antimicrobial agents and chemotherapy, 38(3), 1994, pp. 547-557
Authors:
HYATT JM
NIX DE
SCHENTAG JJ
Citation: Jm. Hyatt et al., PHARMACOKINETIC AND PHARMACODYNAMIC ACTIVITIES OF CIPROFLOXACIN AGAINST STRAINS OF STREPTOCOCCUS-PNEUMONIAE, STAPHYLOCOCCUS-AUREUS, AND PSEUDOMONAS-AERUGINOSA FOR WHICH MICS ARE SIMILAR, Antimicrobial agents and chemotherapy, 38(12), 1994, pp. 2730-2737
Authors:
LI RC
NIX DE
SCHENTAG JJ
Citation: Rc. Li et al., PHARMACODYNAMIC MODELING OF BACTERIAL KINETICS - BETA-LACTAM ANTIBIOTICS AGAINST ESCHERICHIA-COLI, Journal of pharmaceutical sciences, 83(7), 1994, pp. 970-975